Age At Time Of Trauma May Determine Long-Term Impact

Trauma During Infancy, Childhood, and Adolescence Each Leave a Different Mark on the Brain

Traumatic experiences often leave a scar behind, whether it be physical, psychological, or emotional. Anyone who has lived through trauma knows that the effects don’t simply fade with time. But a new study raises a question that researchers have struggled to answer for years. Why do some people develop depression while others report aggression, anxiety, or attention problems, even after going through comparable traumatic ordeals?

According to research published in Cell Reports Medicine, one of the biggest factors may not be what happened, but how old a person was when it did. Scientists found that the age at which trauma occurs appears to shape long-term mental health outcomes more than the specific type of traumatic event, a finding that could change how clinicians think about treatment and diagnosis for millions of people.

The study, led by researchers at the Istituto Italiano di Tecnologia in Genoa, Italy, used mouse experiments paired with human data to reach its conclusions. Importantly, the strongest cause-and-effect evidence came from the animal work; the human data showed similar patterns but cannot prove that timing caused those outcomes.

Trauma Timing Drives Different Mental Health Profiles

Researchers exposed mice to two different types of frightening experiences, including exposure to a predator scent and brief underwater submersions, at four distinct life stages: infancy, childhood, adolescence, and young adulthood. All animals were tested as adults, well after the stressful experiences had ended.

What trauma type the mice experienced mattered far less than when it happened. Mice stressed during infancy grew up to be socially withdrawn and submissive. Those stressed during childhood developed significant attention problems as adults. Adolescent stress produced dominant, aggressive behavior. Trauma during young adulthood led to a different cluster: depression-like symptoms, social difficulties, and heightened anxiety.

Anxiety-related behaviors were the one exception, showing up across all age groups regardless of when stress occurred. That tracks with what’s already established in humans: anxiety disorders are among the most common long-term effects of trauma at any age.

Mouse and Human Data Tell a Similar Story

One of the study’s more carefully constructed aspects is the parallel it draws between animal findings and human data from two separate sources.

Researchers analyzed preserved brain tissue from the prefrontal cortex, the brain region involved in decision-making and emotional regulation, of deceased adults who had experienced trauma either before or after age 12. Protein changes in those human samples mirrored what the team found in mice. People who experienced trauma after age 12 showed far greater changes in the prefrontal cortex, consistent with what the adolescent and young adult mice displayed.

Researchers also reviewed records from 72 children and teenagers treated at a pediatric psychiatric center in Italy, all with documented trauma histories. Sorted by age at trauma, clear patterns emerged. Children traumatized between ages zero and five mostly struggled with social connection. Those traumatized between six and twelve frequently showed signs consistent with attention-deficit hyperactivity disorder. Teenagers who experienced trauma tended toward aggressive or dominant behavior. Statistical analysis confirmed the links between trauma timing and specific behavioral outcomes were not due to chance.

The 209 mice in the behavioral experiments and 35 human brain tissue samples in the protein analysis formed the core of the dataset, alongside the 72 clinical patients.

A Cancer Drug Points Toward a Possible Treatment Path

Beyond mapping how timing shapes outcomes, the researchers looked for potential treatment targets. In mice traumatized during young adulthood specifically, a protein called TrkB, a receptor that interacts with BDNF (brain-derived neurotrophic factor, a molecule that supports nerve cell growth and emotional processing), was elevated across multiple brain regions.

Reasoning that blocking this overactive receptor might ease the behavioral problems, the team administered larotrectinib, an FDA-approved cancer drug that targets TrkB, to mice that had been stressed during young adulthood. In those animals, the drug fully resolved dominant and depression-like behavior, and fully resolved anxiety and compulsive behavior patterns. Social deficits were partially improved.

When researchers gave the same drug to mice traumatized during infancy, it did not improve their dominant or social behavior. That confirmed the effect appears specific to trauma experienced during young adulthood, not trauma in general.

The human brain tissue analysis also found BDNF-related protein changes in adults who had experienced trauma after age 12 and had depression, mirroring the young adult mouse findings. That parallel adds weight to TrkB inhibition as a pathway worth investigating, though it does not mean larotrectinib should be used for trauma-related mental health conditions in people. No human clinical trials have tested the drug for that purpose.

For clinicians and researchers trying to understand why the same event can leave one person with ADHD-like symptoms and another with depression, the answer according to this study may lie less in what happened and more in when the developing brain first encountered it.

---

Disclaimer: This article is based on published scientific research. The findings described, particularly those involving the drug larotrectinib, are preliminary and derived from animal studies. They should not be interpreted as medical advice or as evidence that any treatment described is safe or effective for use in humans.

---